NCT01082419

Brief Summary

Liver stiffness measurement (LSM) by non invasive methods is increasingly used to estimate liver fibrosis in patients with chronic liver diseases. However, there is growing evidence that fibrosis is not the only determinant of liver stiffness. Indeed inflammation, cholestasis, congestion could also interfere with stiffness measurements. Acoustic radiation force impulse imaging (ARFI) is a new technology to perform real time LSM. Using a standard ultrasonographic probe, it offers elastography with a flexible metering box at variable depth, allowing the examination of specific area.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
109

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 5, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 8, 2010

Completed
24 days until next milestone

Study Start

First participant enrolled

April 1, 2010

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
Last Updated

November 7, 2014

Status Verified

November 1, 2014

Enrollment Period

3 years

First QC Date

March 5, 2010

Last Update Submit

November 6, 2014

Conditions

Keywords

Liver stiffness measurementARFIfibrosishepatopathy

Outcome Measures

Primary Outcomes (1)

  • The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.

    One or two 30 min visit according to the patient group

Secondary Outcomes (2)

  • Inter and intra observer reproducibility

    Three 30 min visits in healthy volunteer group.

  • Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease

    From patient admission until patient healing in groups F&G.

Study Arms (7)

Group A

OTHER

healthy volunteers

Device: ARFI measurement

Group B

OTHER

patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)

Device: ARFI measurement

Group D

OTHER

patients with cirrhosis

Device: ARFI measurement

Group E

OTHER

patients with liver tumour and surgery indication

Device: ARFI measurement

Group F

OTHER

patients with reversible liver diseases and with acute left cardiac insufficiency

Device: ARFI measurement

Group C

OTHER

patients with non cirrhotic hepatopathy

Device: ARFI measurement

Group G

OTHER

patients with reversible liver diseases and with biliary cholestasis

Device: ARFI measurement

Interventions

ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a "light" apnea. For group A the measurement is made by a second and a third investigator during the same examination.

Group A

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Man or Woman
  • Age\> 18 years old
  • Able to understand the study and to give informed consent
  • Informed consent signed by patient and investigator before any study required examination
  • With a valid health insurance
  • Group A : healthy volunteers without known liver disease
  • Group B : voluntary patients without known liver disease
  • Group C and D Patient with a diagnosed chronic liver disease
  • Group E : patients with liver tumors (benign or malignant) with surgical indication
  • Group F : patients with acute right heart insufficiency diagnosed by a cardiologist
  • Group G :patients with biliary cholestasis and imaging evidence of biliary dilatation

You may not qualify if:

  • Patient under 18 years old
  • Not able to understand the study or to give their consent.
  • Pregnant woman
  • Severe respiratory insufficiency
  • Unable to perform a "light" apnea .
  • hemodynamic instability (cardiogenic shock, septic or anaphylactic) possibility of disruption of the elasticity and inability to carry patient.
  • Chronic heart insufficiency.
  • deprived of their liberty by court

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Bordeaux

Bordeaux, 33075, France

Location

Related Publications (5)

  • Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol. 2009 Jan;50(1):17-35. doi: 10.1016/j.jhep.2008.10.016. Epub 2008 Nov 8.

    PMID: 19022517BACKGROUND
  • Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008 May;48(5):835-47. doi: 10.1016/j.jhep.2008.02.008. Epub 2008 Feb 26.

    PMID: 18334275BACKGROUND
  • Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034. Epub 2008 Jan 18.

    PMID: 18395077BACKGROUND
  • Ferraioli G, Gulizia R, Filice C. Real-time elastography in the assessment of liver fibrosis. AJR Am J Roentgenol. 2007 Sep;189(3):W170. doi: 10.2214/AJR.07.2318. No abstract available.

    PMID: 17715090BACKGROUND
  • Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol. 2007 Mar;188(3):758-64. doi: 10.2214/AJR.06.0322.

    PMID: 17312065BACKGROUND

MeSH Terms

Conditions

Liver CirrhosisCarcinoma, HepatocellularHeart FailureFibrosisDigestive System Diseases

Condition Hierarchy (Ancestors)

Liver DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteHeart DiseasesCardiovascular Diseases

Study Officials

  • Nora FRULIO, Md MSc

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR
  • Adelaïde Doussau, MD, Msc

    University Hospital, Bordeaux

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 5, 2010

First Posted

March 8, 2010

Study Start

April 1, 2010

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

November 7, 2014

Record last verified: 2014-11

Locations